Patient-reported outcomes in PROSPECT trial (Alliance N1048) - FOLFOX is not a panacea.
作者信息
O'Cathail Sean M, Adams Richard, Hawkins Maria A, Sebag-Montefiore David, Marijnen Corrie A M, Fokas Emmanouil
机构信息
School of Cancer Sciences, University of Glasgow & Beatson Cancer Centre, Glasgow, UK.
Velindre Cancer Centre, Cardiff, UK.
出版信息
Clin Transl Radiat Oncol. 2023 Aug 30;43:100672. doi: 10.1016/j.ctro.2023.100672. eCollection 2023 Nov.
Abstract
摘要
相似文献
1
Patient-reported outcomes in PROSPECT trial (Alliance N1048) - FOLFOX is not a panacea.PROSPECT试验（联盟N1048）中患者报告的结局——FOLFOX并非万灵药。
Clin Transl Radiat Oncol. 2023 Aug 30;43:100672. doi: 10.1016/j.ctro.2023.100672. eCollection 2023 Nov.
2
PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium.泛加拿大直肠癌联盟的前景：资格与临床结果。
Clin Colorectal Cancer. 2016 Sep;15(3):243-9. doi: 10.1016/j.clcc.2016.02.003. Epub 2016 Feb 13.
3
Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.局部进展期直肠癌行全直肠系膜切除术联合辅助 FOLFOX 化疗的 upfront 根治性手术（TME-FOLFOX）：一项开放标签、多中心、二期随机对照临床试验。
Trials. 2020 Apr 7;21(1):320. doi: 10.1186/s13063-020-04266-6.
4
Evolving role of neoadjuvant therapy in rectal cancer.新辅助治疗在直肠癌中的作用演变。
Curr Treat Options Oncol. 2013 Sep;14(3):350-64. doi: 10.1007/s11864-013-0242-8.
5
Quality of Life Outcomes From a Phase 2 Trial of Short-Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer.短程放疗后序贯FOLFOX化疗作为直肠癌术前治疗的2期试验的生活质量结果
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1429-1438. doi: 10.1016/j.ijrobp.2016.03.020. Epub 2016 Mar 25.
6
Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review.FOLFOX方案同步放化疗治疗食管鳞状细胞癌合并直肠癌：4例病例报告及文献综述
Mol Clin Oncol. 2020 Jan;12(1):23-30. doi: 10.3892/mco.2019.1945. Epub 2019 Oct 31.
7
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.奥沙利铂、氟尿嘧啶和亚叶酸钙与氟尿嘧啶和亚叶酸钙作为术前放化疗后局部进展期直肠癌的辅助化疗（ADORE）：一项开放标签、多中心、2 期、随机对照临床试验。
Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4.
8
Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery.Ⅱ/Ⅲ期直肠癌根治性手术患者单纯化疗
Oncologist. 2015 Jul;20(7):752-7. doi: 10.1634/theoncologist.2015-0038. Epub 2015 Jun 3.
9
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial.奥沙利铂为基础的辅助化疗在术前放化疗后直肠癌（ADORE）：随机对照试验的长期结果。
J Clin Oncol. 2019 Nov 20;37(33):3111-3123. doi: 10.1200/JCO.19.00016. Epub 2019 Oct 8.
10
Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer.新辅助FOLFOX方案不联合放疗用于基线可切除直肠癌的可行性
In Vivo. 2018 Jul-Aug;32(4):937-943. doi: 10.21873/invivo.11332.
引用本文的文献
1
Rectal stenosis after immunotherapy in a mismatch repair deficient rectal cancer. Case report and review of literature.错配修复缺陷型直肠癌免疫治疗后发生直肠狭窄。病例报告及文献综述。
Clin Transl Radiat Oncol. 2025 Apr 9;53:100953. doi: 10.1016/j.ctro.2025.100953. eCollection 2025 Jul.
2
Short- and long-term outcomes of neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an updated meta-analysis.新辅助化疗与新辅助放化疗治疗局部晚期直肠癌的短期和长期结局比较：一项更新的荟萃分析
BMC Gastroenterol. 2025 Feb 17;25(1):87. doi: 10.1186/s12876-025-03667-8.
3
Management of patients with reduced dihydropyrimidine dehydrogenase activity receiving combined 5-fluoruracil-/capecitabine-based chemoradiotherapy.二氢嘧啶脱氢酶活性降低的患者接受基于5-氟尿嘧啶/卡培他滨联合放化疗的管理。
Strahlenther Onkol. 2024 Sep 4. doi: 10.1007/s00066-024-02287-7.
本文引用的文献
1
Preoperative Treatment of Locally Advanced Rectal Cancer.局部进展期直肠癌的术前治疗。
N Engl J Med. 2023 Jul 27;389(4):322-334. doi: 10.1056/NEJMoa2303269. Epub 2023 Jun 4.
2
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).在 PROSPECT 试验（Alliance N1048）中局部晚期直肠癌治疗期间和治疗后的患者报告结局。
J Clin Oncol. 2023 Jul 20;41(21):3724-3734. doi: 10.1200/JCO.23.00903. Epub 2023 Jun 4.
3
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.PD-1 阻断在错配修复缺陷、局部晚期直肠癌中的应用。
N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5.
4
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer.国际共识推荐意见：直肠癌患者接受（放）化疗后器官保存的关键结局指标
Nat Rev Clin Oncol. 2021 Dec;18(12):805-816. doi: 10.1038/s41571-021-00538-5. Epub 2021 Aug 4.
5
Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020.2020 年英国直肠癌调强放疗。
Clin Oncol (R Coll Radiol). 2021 Apr;33(4):214-223. doi: 10.1016/j.clon.2020.12.011. Epub 2021 Jan 8.
6
Outcome measures in multimodal rectal cancer trials.多模态直肠癌临床试验的结局指标。
Lancet Oncol. 2020 May;21(5):e252-e264. doi: 10.1016/S1470-2045(20)30024-3.
7
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.直肠癌：欧洲肿瘤内科学会临床实践指南之诊断、治疗及随访
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40. doi: 10.1093/annonc/mdx224.
8
Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer.术前放化疗后辅助化疗疗效证明面临的挑战。
Lancet Oncol. 2017 Jun;18(6):e354-e363. doi: 10.1016/S1470-2045(17)30346-7.
9
Technological advances in radiotherapy of rectal cancer: opportunities and challenges.直肠癌放射治疗的技术进展：机遇与挑战
Curr Opin Oncol. 2016 Jul;28(4):353-8. doi: 10.1097/CCO.0000000000000306.
Zotero 插件